DelveInsight’s, “Ovarian Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Ovarian Cancer Pipeline Report

• DelveInsight’s Ovarian Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Ovarian Cancer treatment.
• The leading companies working in the Ovarian Cancer Market include IMV, Elucida Oncology, Chia Tai Tianqing Pharmaceutical Group, Precigen Inc., Glycotope GmbH, Sonnet Biotherapeutics, Allarity Therapeutics, Adimab/Mersana Therapeutics, Genentech, Genmab, Merck, OncoQuest, IMPACT Therapeutics, and others.
• Promising Ovarian Cancer Pipeline Therapies in the various stages of development include SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.
• November 2023: Bayer announced a study of Phase 1 clinical trials for Elimusertib (BAY1895344) and Niraparib. The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib. In addition researchers want to find for patients the optimal dose of elimusertib in combination with niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication elimusertib works by blocking a substance produced by the body (ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.
• November 2023: Gradalis Inc. announced a study of Phase 2 clinical trials for Vigil.  The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is “Will participants who receive treatment with Vigil have a longer time to disease recurrence versus the participants that were not given Vigil?”
• October 2023: AstraZeneca announced a study of Phase 2 clinical trials for olaparib, paclitaxel and carboplatin.To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
• October 2023: Sonnet Bio Therapeutics announced a study of Phase 1 & 2 clinical trials for SON-1010. This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2).

 

Request a sample and discover the recent advances in Ovarian Cancer Treatment Drugs @ Ovarian Cancer Pipeline Report

 

In the Ovarian Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Ovarian Cancer Overview

Ovarian Cancer is a type of cancer that begins in a woman’s ovaries – the small organs in the female reproductive system that create eggs. This kind of cancer can be difficult to detect because it often doesn’t cause any symptoms until later stages. Once found, Ovarian Cancer can be treated with chemotherapy and surgery to remove any tumors.

 

Find out more about Ovarian Cancer Therapeutics Assessment @ Ovarian Cancer Preclinical and Discovery Stage Products

 

Ovarian Cancer Emerging Drugs Profile

• Atezolizumab: Genentech
• Tisotumab Vedotin: Genmab
• Pembrolizumab: Merck

 

Ovarian Cancer Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Ovarian Cancer. The Ovarian Cancer companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Ovarian Cancer Pipeline report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Ovarian Cancer Pipeline Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Learn more about the emerging Ovarian Cancer Pipeline Therapies @ Ovarian Cancer Clinical Trials Assessment

 

Scope of the Ovarian Cancer Pipeline Report

• Coverage- Global
• Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ovarian Cancer Companies- IMV, Elucida Oncology, Chia Tai Tianqing Pharmaceutical Group, Precigen Inc., Glycotope GmbH, Sonnet Biotherapeutics, Allarity Therapeutics, Adimab/Mersana Therapeutics, Genentech, Genmab, Merck, OncoQuest, IMPACT Therapeutics, and others.
• Ovarian Cancer Pipeline Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.

 

Dive deep into rich insights for new drugs for Ovarian Cancer Treatment, Visit @ Ovarian Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ovarian Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tisotumab Vedotin: Genmab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ovarian Cancer Key Companies
21. Ovarian Cancer Key Products
22. Ovarian Cancer- Unmet Needs
23. Ovarian Cancer- Market Drivers and Barriers
24. Ovarian Cancer- Future Perspectives and Conclusion
25. Ovarian Cancer Analyst Views
26. Ovarian Cancer Key Companies
27. Appendix

 

For further information on the Ovarian Cancer Pipeline therapeutics, reach out to Ovarian Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/liver-fibrosis-market